Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.49
-$0.26(-3.11%)
At close: 4:00 PM EST
$9.49
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)2.08M
Market Cap
$686.54M
Enterprise Value$464.25M
Total Cash (Recent Filing)$150.49M
Total Debt (Recent Filing)$71.07M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Aug 05, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.60
Shares Outstanding51,697,620
10 Day Avg. Volume1,869,135
30 Day Avg. Volume2,084,770
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue5.29
Enterprise Value/Gross Profit-3.87K
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$20.89Price Target Upside120.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$233.44M
Bulls Say, Bears Say
Bulls Say
Proprietary NAV AAV Platform & Partner ModelThe NAV AAV vector is a durable competitive asset that enables licensing, milestone and royalty revenues across multiple partners. This diversified, platform-driven model spreads scientific and commercial risk, supports recurring non-product revenue and enhances long-term strategic optionality.
Pivotal RGX-202 Phase III Success And Surrogate LinkageMeeting the pivotal endpoint with strong biomarker readouts and reported >0.9 correlation to functional measures materially strengthens the case for microdystrophin as a surrogate. That de-risks regulatory path and supports accelerated approval strategies, improving long-term commercialization prospects.
Near-term Non-dilutive Milestone Funding From AbbVieA $100M partner milestone provides meaningful near-term cash without dilution, extending runway and enabling continued pivotal programs and regulatory work. This non-dilutive funding reduces immediate financing pressure and preserves strategic flexibility into key 2026–2027 milestones.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowSustained large negative operating and free cash flows mean the business is not self-funding and must rely on partner milestones, financing or dilution to continue operations. Prolonged burn increases execution risk if clinical or regulatory timelines slip and raises funding cost over time.
High Leverage And Thin Equity CushionElevated leverage versus a very small equity base weakens the balance sheet and heightens refinancing and covenant risk. A thin equity cushion limits capacity to absorb further losses and increases the likelihood of dilutive financings or constrained strategic choices if setbacks occur.
Regulatory Uncertainty Around External ControlsIf regulators require randomized controlled trials instead of external controls, approval timelines and costs could lengthen materially. Such a structural regulatory hurdle would delay revenue, increase development expense and strain cash runway and partner timelines over multiple years.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $686.54M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 29 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on May 14, 2026. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$0.383.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is 0.25.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 51,697,620 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went down -37.799%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.89 (120.11% Upside)
$20.89 (120.11% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 329.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.06%
12-Months-Change
Fundamentals
Return on Equity
-232.50%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$20.89
▲(120.11% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.88% Insiders
17.41% Mutual Funds
0.05% Other Institutional Investors
57.80% Public Companies and
Individual Investors